

## La Jolla Pharmaceutical Company

[View the current La Jolla Pharmaceutical Company Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/6234-La+Jolla+Pharmaceutical+Company.html)

(<http://www.bioportfolio.com/biocorporate/6234-La+Jolla+Pharmaceutical+Company.html>)

### Contact Details:

6455 Nancy Ridge Drive

San Diego

California

92121

United States of America

Tel: (858) 452-6600

Fax: (858) 626-2851

Email:

La Jolla Pharmaceutical Company ("La Jolla") is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The NASDAQ Global Market under the symbol LJPC.

### Recent Publications by La Jolla Pharmaceutical Company:



- [Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation.](#)

*Abetimus sodium is an oligonucleotide-based investigational drug designed...* 4th November, 2008

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA- J Clin Pharmacol. 2008 Aug;48(8):909-18. Epub 2008 May 29. ([DOI Direct Link](#))

- [Anti-inflammatory effects of LJP 1586 \[Z-3-fluoro-2-\(4-methoxybenzyl\)allylamine hydrochloride\], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity.](#)

*Semicarbazide-sensitive amine oxidase (SSAO, amine oxidase,...* 20th February, 2008

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA- J Pharmacol Exp Ther. 2008 Feb;324(2):867-75. Epub 2007 Nov 9. ([DOI Direct Link](#))

- [Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis.](#)

*We have developed several series of potent and selective small molecule...* 6th December, 2007

La Jolla Pharmaceutical Company, San Diego, CA 92121, USA.- J Neural Transm. 2007;114(6):845-9. Epub 2007 Mar 29. ([DOI Direct Link](#))

- [Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase \(SSAO\)](#)

[inhibitors with anti-inflammatory activity.](#)

*In an attempt to examine the effect of inhibition of...*4th May, 2006

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego,- J Med Chem. 2006 Apr 6;49(7):2166-73. ([DOI Direct Link](#))

- [Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases.](#)

*This review covers the design and development of B cell Toleragens,...*9th March, 2006

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Dr., San Diego, CA- Curr Med Chem. 2005;12(16):1887-904.

- [Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.](#)

*Human semicarbazide-sensitive amine oxidase (SSAO) or vascular adhesion...*13th January, 2006

La Jolla Pharmaceutical Company, San Diego, CA 92121, USA.- J Pharmacol Exp Ther. 2005 Nov;315(2):553-62. Epub 2005 Aug 4. ([DOI Direct Link](#))

- [Therapeutic potential of toleragens in the management of antiphospholipid syndrome.](#)

*Autoantibodies to beta2-glycoprotein I (beta2GPI) are believed to be the...*5th August, 2005

La Jolla Pharmaceutical Company, San Diego, California, USA.- BioDrugs. 2004;18(5):297-305.

- [Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus.](#)

*OBJECTIVE: To examine the relationship between changes in...*13th May, 2005

La Jolla Pharmaceutical Company, San Diego, California 92121, USA.- Arthritis Rheum. 2005 Apr;52(4):1129-37. ([DOI Direct Link](#))

- [Advances in understanding what we measure when detecting anticardiolipin autoantibodies.](#)

*Understanding so-called anticardiolipin autoantibodies has been the focus...*16th December, 2004

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA- Clin Chim Acta. 2004 May;343(1-2):37-44. ([DOI Direct Link](#))

- [Detection and characterization of B cell epitopes on beta2-glycoprotein I.](#)

*Autoantibodies in antiphospholipid syndrome react predominantly with the...*19th August, 2004

La Jolla Pharmaceutical Company, San Diego, CA 92121, USA.- Clin Immunol. 2004 Aug;112(2):129-35. ([DOI Direct Link](#))

- [Multivalent poly\(ethylene glycol\)-containing conjugates for in vivo antibody suppression.](#)

*Poly(ethylene glycol) (PEG) was incorporated into multivalent conjugates...*10th July, 2004

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego,- Bioconjug Chem. 2003 Nov-Dec;14(6):1067-76. ([DOI Direct Link](#))

- [In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome.](#)

*This study investigated the use of well-defined bioconjugate molecules to...*15th June, 2004

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA- Int Immunopharmacol. 2003 Nov;3(12):1667-75. ([DOI Direct Link](#))

## Press Releases on La Jolla Pharmaceutical Company:

[Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference](#)

20th November, 2009

Centene Corporation

ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,

[Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal](#)

20th November, 2009

Cornerstone Therapeutics Inc.

CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products

[Case Studies Offer Inside Look at Effective Ways to Address Global Health Challenges](#)

20th November, 2009

Alliance for Case Studies for Global Health

Publication to Serve as Guide to Understanding, Building Productive Partnerships WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Meaningful and lasting progress in addressing global health challenges

[Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results](#)

20th November, 2009

Landauer, Inc.

GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), will release financial results for the fiscal fourth quarter and full year of 2009 pre-market on Tuesday, December 1, 2009

[Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost](#)

20th November, 2009

Medco Health Solutions, Inc.

NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc (NYSE: MHS) is today contributing to a transformation in American healthcare through an advanced, wired pharmacy paradigm that

## BioNews Results for La Jolla Pharmaceutical Company



- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)  
*StockHouse USA: Nov 10 2009 12:06AM Matching: la jolla pharmaceutical company*
- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)  
*Yahoo! Canada: Nov 10 2009 12:10AM Matching: la jolla pharmaceutical company*
- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)  
*Genetic Engineering News: Nov 10 2009 12:50AM Matching: la jolla pharmaceutical company*
- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)  
*Silicon Investor: Nov 10 2009 3:43AM Matching: la jolla pharmaceutical company*
- [La Jolla Pharmaceutical Company Reschedules Special Meeting of Stockholders](#)  
*Individual.com: Nov 5 2009 11:59PM Matching: la jolla pharmaceutical company*
- [News and FDA Updates for Herbalife \(NYSE:HLF\), Antares Pharma \(Amex: AIS\), La Jolla \(NASDAQ: LJPC\)](#)  
*Los Angeles Chronicle: Nov 5 2009 4:40AM Matching: la jolla pharmaceutical company*
- [News and FDA Updates for Herbalife \(NYSE:HLF\), Antares Pharma \(Amex: AIS\), La Jolla](#)

[\(NASDAQ:LJPC\)](#)

*American Chronicle: Nov 4 2009 10:27AM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*Individual.com: Nov 3 2009 12:29AM Matching: la jolla pharmaceutical company*

- [BiomedReports: News and FDA Updates for Herbalife \(NYSE:HLF\), Antares Pharma \(Amex:AIS\), La Jolla \(NASDAQ:LJPC\)](#)

*TradingMarkets: Nov 3 2009 4:00PM Matching: la jolla pharmaceutical company*

- [BiomedReports: News and FDA Updates for Herbalife \(NYSE:HLF\), Antares Pharma \(Amex:AIS\), La Jolla \(NASDAQ:LJPC\)](#)

*RBC Dain Rauscher: Nov 3 2009 3:17PM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*SmartBrief: Nov 3 2009 4:43AM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*Pharma Live: Nov 2 2009 10:07PM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*Street Insider: Nov 2 2009 8:22PM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*NewsBlaze: Nov 2 2009 8:15PM Matching: la jolla pharmaceutical company*

- [La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders](#)

*CNBC: Nov 2 2009 8:39PM Matching: la jolla pharmaceutical company*

#### La Jolla Pharmaceutical Company Clinical Trials:



- [Study of LJP 394 in Lupus Patients With History of Renal Disease](#)

#### La Jolla Pharmaceutical Company Patents:



- 7351855- [Chemically defined non-polymeric valency platform molecules and conjugates thereof](#)
- 5874409- [APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies](#)
- 5817752- [Cyclic polypeptides comprising a thioether linkage and methods for their preparation](#)
- 5726329- [Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides](#)
- 5633395- [Chemically-defined non-polymeric valency platform molecules and conjugates thereof](#)
- 5606047- [Chemically-defined non-polymeric valency platform molecules and conjugates thereof](#)
- 5552391- [Chemically-defined non-polymeric valency platform molecules and conjugates thereof](#)
- 5276013- [Conjugates of biologically stable polyfunctional molecules and polynucleotides for treating](#)

## [systemic lupus erythematosus](#)

- 5268454- [Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier](#)
- 5162515- [Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus](#)
- 5017648- [D-GL conjugate therapy](#)
- 4950713- [Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals](#)
- 5874552- [Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides](#)
- 6031073- [Cyclic polypeptides comprising a thioether linkage and methods for their preparation](#)
- 6060056- [Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule](#)
- 7208156- [Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule](#)
- 7163683- [Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule](#)
- 7138244- [Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule](#)
- 7115581- [Chemically-defined non-polymeric valency platform molecules and conjugates thereof](#)
- 7081242- [Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof](#)
- 6951939- [Multivalent platform molecules comprising high molecular weight polyethylene oxide](#)
- 6458953- [Valency platform molecules comprising carbamate linkages](#)
- 6410775- [APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies](#)
- 6399578- [Conjugates comprising galactose .alpha.1,3 galactosyl epitopes and methods of using same](#)
- 6207160- [aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies](#)
- 6166198- [Methods for oligonucleotide synthesis](#)
- 4950469- [D-GL conjugate therapy](#)

## **BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

